Articles from Circulation

Link to journal online

WRITING COMMITTEE MEMBERS; Douglas, Pamela S. , Chair; Hendel, Robert C. Co-Chair; Cummings, Jennifer E. et al,ACCF/ACR/AHA/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR 2008 Health Policy Statement on Structured Reporting in Cardiovascular Imaging
Publish Ahead of Print, published online before print, 8 December 2008

WRITING COMMITTEE MEMBERS; Hendel, Robert C. , Chair; Budoff, Matthew J. et al
ACC/AHA/ACR/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SIR 2008 Key Data Elements and Definitions for Cardiac Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Cardiac Imaging)
Publish Ahead of Print, published online before print, 8 December 2008

Nicholls, Stephen J.; Tuzcu, E Murat ; Brennan, Danielle M. et al
Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)
118(24):2506-2514, December 9, 2008.
Abstract
Background-: Despite favorable effects on high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol, the cholesteryl ester transfer protein inhibitor torcetrapib failed to slow atherosclerosis progression and increased mortality. We investigated the relationship between lipid changes and progression of coronary atherosclerosis.Methods and Results-: Intravascular ultrasound was performed at baseline and follow-up in 910 participants randomized to torcetrapib/atorvastatin or atorvastatin monotherapy. The relationship between changes in lipoprotein levels and the primary intravascular ultrasound end point, change in percent atheroma volume, was investigated. Compared with atorvastatin monotherapy, torcetrapib raised HDL-C by 61%, lowered low-density lipoprotein cholesterol by 20%, raised serum sodium (0.44+/-0.14 mmol/L, P=0.02), and lowered serum potassium (0.11+/-0.02 mmol/L, P<0.0001). r="-0.17," p="0.002)." p="0.001)." p="0.01)." p="0.001).Conclusions-:">

Josephs, Shellie C. MD, Chair; Rowley, Howard A. MD; Rubin, Geoffrey D. MD; for Writing Group 3
Atherosclerotic Peripheral Vascular Disease Symposium II: Vascular Magnetic Resonance and Computed Tomographic Imaging.[Abstract]
118(25):2837-2844, December 16/23, 2008.